Muscle fibrillin deficiency in Marfan's syndrome myopathy

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 5, 2003, Pages 633-638

  Behan, W M H ^a,b   Longman, C ^b   Petty, R K H ^b   Comeglio, P ^c   Child, A H ^c   Boxer, M ^b   Foskett, P ^b   Harriman, D G F ^d  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; FIBRILLIN; GENOMIC DNA; MONOCLONAL ANTIBODY; WARFARIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; EXON; FAMILY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG FUNCTION TEST; MALE; MARFAN SYNDROME; MUSCLE BIOPSY; MYOPATHY; NEUROLOGIC EXAMINATION; PEDIGREE; PHYSICAL EXAMINATION; POINT MUTATION; PRIORITY JOURNAL; RESPIRATORY FAILURE;

ADOLESCENT; ADULT; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MARFAN SYNDROME; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCULAR DISEASES; PEDIGREE; RESPIRATORY INSUFFICIENCY; RESPIRATORY MUSCLES;

EID: 0037623561     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.5.633     Document Type: Article

References (39)

1. Pyeritz RE. The Marfan syndrome. Ann Rev Med 2000,51:481-510.
2. Dietz H, Ramirez F, Sakai L. Marfan syndrome and other microfibrillar diseases. In: Harris H, Hirschhorn K, eds. Advances in human genetics, vol 22. New York: Plenum Press, 1994:153-86.
3. Pyeritz RE, McKusick VA. The Marfan syndrome: diagnosis and management. N Engl J Med 1979;300:772-7.
4. McKusick VA. The Marfan syndrome. In: Heritable disorders of connective tissue, 4th ed. St Louis: CV Mosby, 1972:61-223.
5. Beighton P, de Paepe A, Danks D, et al. International nosology of heritable disorders of connective tissue, Berlin, 1986. Am J Med Genet 1988;29:581-94.
6. De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-26.
7. de Paepe A. Dural ectasia and the diagnosis of Marfan's syndrome. Lancet 1999;354:878-9.
8. Marfan AB. Un cas de déformation congénitale des quatres membres, plus prononcée aux extrémités caractérisée par l'allongement des os avec un certain degree d'amincissement. Bull Mem Soc Med Hop (Paris) 1896;13:220-6.
9. Young ML. Arachnodactyly. Arch Dis Child 1929;4:190-209.
10. Fulcher PH, Southworth H. Arachnodactyly and its medical complications. Arch Intern Med 1938;61:693-703.
11. Lambie CG, Shellshear KE, Shellshear JL. Arachnodactyly or Marfan's syndrome. Med J Austr 1950;1:213-23.
12. Robinson PN, Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. J Med Genet 2000;37:9-25.
13. Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350 kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol 1986;103:2499-509.
14. Zhang H, Hu W, Ramirez F. Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrils. J Cell Biol 1995;129:1165-76.
15. Gibson MA, Finnis ML, Kumaratilake JS, et al. Microfibril-associated glycoprotein-2 (MAGP-2) is specifically associated with fibrillin-containing microfibrils but exhibits more restricted patterns of tissue localisation and developmental expression than its structural relative MAGP-1. J Histochem Cytochem 1998;46:871-8.
16. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo nonsense mutation in the fibrillin gene. Nature 1991;352:337-9.
17. Collod G, Babron MC, Jondeau G, et al. A second locus for Marfan syndrome maps to chromosome 3p24.2-p25. Nat Genet 1994;8:264-8.
18. Behan WMH, More IAR, Behan PO. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991;83:61-5.
19. Beesley JE. Multiple immunolabelling techniques, in: Beesley JE, ed. Immunocytochemistry. A practical approach. Oxford: Oxford University Press, 1993:103-25.
20. Nijbroek G, Sood S, McIntosh I, et al. Fifteen novel FBN 1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet 1995;57:8-21.
21. Pereira L, Levran O, Ramirez, et al. A molecular approach to the stratification of cardiovascular risk in families with Marfan's syndrome. N Engl J Med 1994;331:148-53.
22. McKusick VA. The Marfan syndrome. In: Heritable disorders of connective tissues, 3rd ed. St Louis: Mosby Kimpton, 1966:52.
23. Hudgson P, Gardner-Medwin D, Fulthorpe JJ, et al. Nemaline myopathy. Neurology 1967;17:1125-42.
24. Cunliffe WJ, Hudgson P, Fulthorpe JJ, et al. A calcitonin-secreting medullary thyroid carcinoma associated with mucosal neuromas, marfanoid features, myopathy and pigmentation. Am J Med 1970;48:120-6.
25. Goebel HH, Muller J, DeMyer W. Myopathy associated with Marfan's syndrome. Neurology 1973;23:1257-68.
26. Gross MLP, Teoh R, Legg NJ, et al. Ocular myopathy and Marfan's syndrome. A family study. J Neurol Sci 1980;46:105-12.
27. Jadro-Santel D, Grcevic N, Dogan S, et al. Centronuclear myopathy with type 1 fibre hypotrophy and "fingerprint" inclusions associated with Marfan's syndrome. J Neurol Sci 1980;45:43-56.
28. Barrison IG, Isenberg DA, Kane SP. Arachnodactyly with unusual neuromyopathic and skeletal abnormalities. J R Soc Med 1980;73:64-8.
29. Joyce DA, Mastaglia FL, Ojeda VJ, et al. Familial myopathy associated with Marfanoid features and multicores. Aust NZ J Med 1984;14:495-9.
30. Pagès M, Echenne B, Pagès A-M, et al. Multicore disease and Marfan's syndrome: a case report. Eur Neurol 1985;24:170-5.
31. Eymard B, Tome FMS, Brunet P, et al. Marfan's syndrome and familial tomaculous neuropathy. A case of fortuitous association. Rev Neurol (Paris) 1986;142:703-5.
32. Kumar P, Gupta D, Sagar RK. A rare combination of Marfan's syndrome, rheumatic heart disease and muscular dystrophy - a case report. Indian Heart J 1994;46:351-2.
33. Hecht F, Beals RK. New syndrome of congenital contractural arachnodactyly originally described by Marfan in 1896. Pediatrics 1972;49:574-9.
34. Putnam EA, Zhang H, Ramirez F, et al. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Nat Genet 1995;11:456-8.
35. Dietz H, McIntoch I, Sakai LY, et al. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics 1993;17:468-75.
36. Hauschka SD. The embryonic origin of muscle. In: Engel AG, Franzini-Armstrong C, eds. Myology, basic and clinical, 2nd ed. New York: McGraw Hill, 1994:19.
37. Halliday D, Hutchinson S, Kettle S, et al. Molecular analysis of eight mutations in FBN1. Hum Genet 1999;105:587-97.
38. Loeys B, Nuytinck L, Delvaux I, et al. Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 2001;161:2447-54.
39. Matyas G, De Paepe A, Halliday D, et al. Evaluation and application of denaturing HPLC for mutation detection in Marfan syndrome: identification of 20 novel mutations and two novel polymorphisms in the FBN1 gene. Hum Mutat 2002;19:443-56.